$KMTS

Umberger Traci S sold $86K of KMTS

Umberger Traci S (See Remarks) sold 3,580 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $24.04 on 2026-08-04.

Original reporting
SEC EDGAR · Umberger Traci S
Published Aug 6, 2026, 11:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The only new information is the insider sale details (shares, price, total value, and post-transaction holdings). There is no accompanying guidance, contract, clinical, or regulatory update.

02

Market read

Traders may note insider selling as a sentiment datapoint, but the disclosure lacks fundamental catalysts and is unlikely to drive sustained repricing.

03

What to watch

The article does not state whether the sale was part of broader compensation, tax planning, or other non-informational motives, and the share count is modest versus typical institutional float.

Relevance 3/10Novelty 3/10Timing: new Form 4 filed 2026-08-06, covering a sale dated 2026-08-04

Background

The article is an SEC Form 4 insider transaction disclosure for Kestera Medical Technologies, Ltd. (KMTS).

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Insider Umberger Traci S sold 3,580 KMTS shares in an open-market transaction for about $86,073, per a new Form 4 filing.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than earnings or guidance-related.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no new operational, financial, or regulatory information that would change KMTS fundamentals.

Market effects

No clear sector read-through from a single, small insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification; absence of a stated 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • KMTS

    Keystera Medical Technologies, Ltd., the company whose insider transaction was reported.

  • Traci S. Umberger

    Officer and director who sold 3,580 shares in an open-market sale.

Related articles

$KMTSMedAI 8/10

Kestra Medical Technologies Q4 Earnings Call Highlights

Kestra Medical Technologies (NASDAQ:KMTS) reported a Q4 GAAP net loss of $38.8 million and adjusted EBITDA loss of $26.7 million. CFO Vaseem Mahboob said gross margin should rise steadily and reiterated confidence in gross margins above 70% over the next few years. The company guided FY2027 revenue to $137 million, up 44% from FY2026, and added a $200 million term loan facility.

$KMTSMed

Kestra Medical Technologies Ltd (KMTS) Q4 2026 Earnings Call Highlights: Record Revenue

Kestra Medical Technologies (KMTS) reported Q4 2026 call highlights. CFO Vaseem Mahboob said fiscal 2027 guidance targets $137 million revenue, driven by prescription volume growth, in-network mix, revenue cycle management improvements, and field expansion, with 44% growth. CEO Brian Webster discussed WCD guideline support, share gains, adding ~40 reps, and refinancing to cut cost of capital by 24% while keeping an M&A option open.

$KMTSMed

Kestra Medical (KMTS) Q4 2026 Earnings Call Transcript

Kestra Medical (KMTS) discussed its FY26 results on an earnings call. Revenue was $95 million for the year, up 59% from FY25, and $28.6 million in Q4, up 66% year over year. Gross margin rose to 51.4% for FY26 (up about 11 pts). The company reported 6.3k prescriptions and expanding sales territories to about 130.

$KMTSMedAI 8/10

Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing

Kestra Medical Technologies (Nasdaq: KMTS) announced a five-year, non-dilutive term loan facility managed by Pharmakon Advisors. It includes $75M funded at closing (used to retire a $45M loan plus fees), $25M available through July 2027, $50M through June 2028 subject to $150M trailing revenue, and a $50M acquisition tranche. Interest is SOFR plus 5.5% with a 3.25% floor; Kestra reported $262M cash/investments as of Apr. 30, 2026.